about
Model structure of human APOBEC3GDeaminase-independent inhibition of parvoviruses by the APOBEC3A cytidine deaminaseThe dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3GHIV-1 replication and APOBEC3 antiviral activity are not regulated by P bodiesMutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificitiesPlunder and stowaways: incorporation of cellular proteins by enveloped virusesDifferential sensitivity of murine leukemia virus to APOBEC3-mediated inhibition is governed by virion exclusion.APOBEC3A and APOBEC3B are potent inhibitors of LTR-retrotransposon function in human cellsRole and mechanism of action of the APOBEC3 family of antiretroviral resistance factorsHIV-1 Vif and APOBEC3G: multiple roads to one goalThe localization of APOBEC3H variants in HIV-1 virions determines their antiviral activityStructural model for deoxycytidine deamination mechanisms of the HIV-1 inactivation enzyme APOBEC3GAPOBEC3G contributes to HIV-1 variation through sublethal mutagenesisHIV-1 Vif, APOBEC, and intrinsic immunityStructure, interaction and real-time monitoring of the enzymatic reaction of wild-type APOBEC3GAPOBEC3G-UBA2 fusion as a potential strategy for stable expression of APOBEC3G and inhibition of HIV-1 replicationHuman APOBEC3G can restrict retroviral infection in avian cells and acts independently of both UNG and SMUG1Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replicationIdentification of APOBEC3DE as another antiretroviral factor from the human APOBEC familyIdentification of amino acid residues in APOBEC3G required for regulation by human immunodeficiency virus type 1 Vif and Virion encapsidation7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3GIntracellular immunity to HIV-1: newly defined retroviral battles inside infected cells.The APOBEC3 family of retroelement restriction factorsSuppression of APOBEC3-mediated restriction of HIV-1 by VifRoles of HIV-1 auxiliary proteins in viral pathogenesis and host-pathogen interactionsNewly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase HStatic magnetic field exposure reproduces cellular effects of the Parkinson's disease drug candidate ZM241385Characterization of the interaction of full-length HIV-1 Vif protein with its key regulator CBFβ and CRL5 E3 ubiquitin ligase componentsA DNA sequence recognition loop on APOBEC3A controls substrate specificityAPOBEC3G: an intracellular centurionAID and Apobec3G haphazard deamination and mutational diversityReduced APOBEC3H variant anti-viral activities are associated with altered RNA binding activities.Vpr14-88-Apobec3G fusion protein is efficiently incorporated into Vif-positive HIV-1 particles and inhibits viral infection.Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteinsModerate strength (0.23-0.28 T) static magnetic fields (SMF) modulate signaling and differentiation in human embryonic cellsInducible APOBEC3G-Vif double stable cell line as a high-throughput screening platform to identify antiviral compounds.Functions and regulation of the APOBEC family of proteinsLeveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS.Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminasesViral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes.
P2860
Q21092257-803107D7-ECD0-4E28-B85E-004F2124E011Q21131577-E1193E3B-1345-44D9-A2F5-C6AD80FD41B3Q21245195-148C86CA-F1D1-4F36-A443-B8D42823034CQ24297395-2BDB05B6-DF70-45E6-8C0A-0CBCD99D0452Q24521469-63E0B919-25F8-4209-9E79-DD3869EE785DQ24524170-B80474AA-0D5D-4987-B4A9-53C9B66672E0Q24529150-4C6E595F-E6BE-49A0-A009-6351956BB41AQ24536003-666C1784-C5A4-4438-8042-5C0AFA9A355DQ24537623-6572DFB0-8AFB-4BB6-BFFD-DC0DD7624AB6Q24564072-32201FB4-678A-4587-A53A-5CB67852E1B4Q24596322-228E0EC4-D4FE-4D7B-90BB-6A13354D2792Q24615413-396FB2DD-B4F2-4354-A0FF-B94AE3399371Q24618320-C40BEB60-B364-4482-B71B-9766A6AAF04CQ24647833-9825A99C-3813-447F-AFD1-37D675B200B1Q24649945-B99249CF-3DB5-4643-800F-7B6661767FC3Q24651400-003818F7-B1AD-4789-A6C0-8893FA7CF4ABQ24655541-F04A97B6-5BF3-41E4-A1BD-C082892819ADQ24669993-E9BE62BC-436C-483B-BC89-4BB69F724A94Q24670173-70CE9C57-8DAB-4BF2-A3AD-1583C2B4F48DQ24672209-DA8E0C6B-62D5-43DD-B0CB-DA22263356EFQ24681427-FDD091E3-8CC8-4502-8BE9-0806AC1E916FQ24805644-B85FC618-5452-4C7B-916F-03389B82EF52Q26862780-A76DDBF8-1EFE-49BF-A4D7-F22E93AF99FDQ27025150-AD346A86-17D9-4C71-8A79-7CA36882AD65Q28286819-A034CB42-D8C6-4D7D-A9B2-0D4C4E161502Q28469134-B4A398BF-C84B-46BA-826B-375A000A349FQ28476027-0C6E0A90-017A-41BE-98FD-1A783BC6E2DFQ28482052-4B3CCC32-0D1A-4172-B7E3-642603735711Q28538801-CDDF5C1B-B487-4E2C-96FA-BDF34A18DDFCQ28754989-31F51154-13AD-45D3-9B7F-87342FA62FD8Q30537745-70627260-7FF3-4872-95D0-3EA961088B10Q31078477-12A90BC7-23BD-474C-A8C5-DA0A4B797648Q33328499-17A45EAD-01D4-4250-A102-3ECD6C10FE5FQ33393637-EA83F916-88E2-4084-8C50-859863962AAEQ33490273-265FCF57-D04A-4FCB-A376-AD8F0E40622FQ33511412-019828DB-2290-4745-B1DC-EC51EC9A5308Q33595661-4AF77798-9F98-4620-8B7A-960648884ECFQ33654949-68C16DDD-8191-467B-AFA3-7CBB698FF7F9Q33731838-C39980A0-F6A2-4027-B0A8-5A2907F2C856Q33755180-AA5189DD-86FA-416A-B4DB-DBD221952D83
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The interaction between HIV-1 Gag and APOBEC3G.
@en
type
label
The interaction between HIV-1 Gag and APOBEC3G.
@en
prefLabel
The interaction between HIV-1 Gag and APOBEC3G.
@en
P2093
P2860
P356
P1476
The interaction between HIV-1 Gag and APOBEC3G
@en
P2093
Jenan Saadatmand
Julien Deflassieux
Lawrence Kleiman
Meijuan Niu
P2860
P304
33177-33184
P356
10.1074/JBC.M402062200
P407
P50
P577
2004-05-24T00:00:00Z